论文部分内容阅读
Pidotimod plays an important role in immunomodulation of human infection disease.Its systematic name is(4R)-3-(5-oxo-L-prolyl)-1,3-thiazolidine-4-carboxylic acid(4R,2S-PDMD).The existence of three optical isomers(4R,2R-PDMD,4S,2R-PDMD,4S,2S-PDMD),producing during different producing procedure,would reduce the efficacy of 4R,2S-PDMD.Thus it is necessary to separate pidotimod and its three optical isomers simultaneously.However,few researches focused on the simultaneous separation of these four pidotimod enantiomers.This study aimed to develop a simultaneous analysis method for the chiral separation of these pidotimod enantiomers based on high performance liquid chromatography(HPLC).The chiral discrimination abilities of four commercialized polysaccharide-based columns,Welch Ultimate(R)Amy-D(4.6 mm×250 mm,5μm),Welch Ultimate(R)Amy-S(4.6 mm×250 mm,5μm),Welch Ultimate(R)Cellu-D(4.6 mm×250 mm,5μm)and Welch Ultimate(R)Cellu-J(4.6 mm×250 mm,5μm),were evaluated.Fourteen mobile phases,including acidic,basic and neutral ones,were applied on the four columns.Based on these mobile phases,Welch Ultimate(R)Amy-D and Welch Ultimate(R)Amy-S were observed to have the potential to separate four pidotimod enantiomers.The mobile phases were then optimized for Ultimate(R)Amy-D and Welch Ultimate(R)Amy-S.Result indicated that only Ultimate(R)Amy-D can get simultaneous baseline separations of four pidotimod enantiomers with the mobile phase of ethanol/methano/trifluoroacetate(90/10/0.1).Untill now,as we know,this is the first report about the simultaneous separations of four pidotimod enantiomers.